ack designation for the development of TKM-Ebola, an anti-Ebola viral therapeutic. The drug is being developed under a $140mn contract with the US. Department of Defense's Medical Countermeasure Systems Bio0efense Therapeutics (MCS-BDTX) Joint Product Management Office. The FDA ascribed a fast track status to this dru